Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales
October 3, 2019
- SymBio Bags Global Rights to Antiviral Brincidofovir from US Biotech, Aiming to Become Hematology Specialty Pharma
October 3, 2019
- Astellas to Make US$13 Million Investment in Boston Area to Support Startups
October 3, 2019
- Health Canada Accepts Mitsubishi Tanabe’s Plant-Derived Flu Vaccine for Review
October 3, 2019
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
- Tsuyoshi Mitsuhashi Appointed as New President of Konica Minolta Precision Medicine
October 2, 2019
- Opdivo Significantly Extends OS against Chemo in Esophageal Cancer
October 2, 2019
- Takara Bio Drops Oncolytic Virus Filing for Melanoma in Japan
October 1, 2019
- ADC-Keytruda Combo Shows ORR of 71% in 1st Line Bladder Cancer: Astellas/Seattle Genetics
October 1, 2019
- Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients
October 1, 2019
- Eisai, Nichi-Iko Team Up for Generic Business in China
October 1, 2019
- AZ to Focus on Asthma-COPD Overlap in Marketing Triple-Combo Therapy Breztri, Will Help GPs Make Diagnosis
September 30, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…